Churchill Downs enters into multi-year agreement with FanDuel 07:07 CHDN
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
Ugh The Children are so angry.
Amylyx price target raised to $50 from $31 at SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
Cantor starts 'fast-growing' Asensus with Overweight, $1.50 target 06:49 ASXC
Applied UV receives $1.5M purchase order for resort in Orlando 08:06 AUVI Applied UV announces…
Applied UV receives $1.5M purchase order for resort in Orlando 08:06 AUVI Applied UV announces…
Boy I need some of this today-
FDA approves Revance's Daxxify injection to improve facial frown lines 07:08 RVNC Revance Therapeutics announced that the United States Food and Drug Administration has approved DAXXIFY, DaxibotulinumtoxinA-lanm, for injection for the temporary improvement of moderate to severe frown lines in adults. DAXXIFY is the first and only neuromodulator stabilized with Peptide Exchange Technology PXT and is free of both human serum albumin and animal-based components.1-2,7-11 Most importantly, DAXXIFY has the ability to address duration of treatment effect, which we believe is the greatest unmet need with existing neuromodulators for both consumers and injectors.12 The FDA approval, Revance's first, augments the company's innovative aesthetics portfolio and expands the company's access to the growing $3.2B U.S. facial injectables market, further establishing Revance as an innovation leader in the industry and laying the groundwork for potential future therapeutic indications.13
FDA approves Revance's Daxxify injection to improve facial frown lines 07:08 RVNC Revance Therapeutics announced that the United States Food and Drug Administration has approved DAXXIFY, DaxibotulinumtoxinA-lanm, for injection for the temporary improvement of moderate to severe frown lines in adults. DAXXIFY is the first and only neuromodulator stabilized with Peptide Exchange Technology PXT and is free of both human serum albumin and animal-based components.1-2,7-11 Most importantly, DAXXIFY has the ability to address duration of treatment effect, which we believe is the greatest unmet need with existing neuromodulators for both consumers and injectors.12 The FDA approval, Revance's first, augments the company's innovative aesthetics portfolio and expands the company's access to the growing $3.2B U.S. facial injectables market, further establishing Revance as an innovation leader in the industry and laying the groundwork for potential future therapeutic indications.13
Mativ director buys $341K in common stock 17:50 MATV In a regulatory filing, Mativ disclosed that its director Jeffrey Keenan bought 15K shares of common stock on September 2nd in a total transaction size of $341K.
The market is often speaking to you if only you would listen.
Yesterday oil was plunging and I mean plunging and which stocks were attracting the most buying? Semi's..? No.--> SOLAR STOCKS.
As an investor in the sector years past I can tell you it is the rare day oil goes down alot and Solar goes up. They always seem in a battle for the the same cash.
Yesterdays action told us that Green Energy ismore than a fad. It'smore than an offset to high oil it's about it'sown growth that isnot stopping.
Growth investors the same ones that might of bought tech, bought solar yesterday. Lots of it.
UPGRADE OF THE DAY-! -- This is a Double Upgrade from Sell to Buy <-- rare
Also it comes with a review of the whole sector and some stks like Shoals, SHLD downgraded. So this is a direct competition upgrade.... And lastly the price target boost is beyond significant $172 from $60.
First Solar upgraded to Buy from Sell at Goldman Sachs 20:53
FSLR
Goldman Sachs analyst Brian Lee upgraded First Solar to Buy from Sell with a price target of $172, up from $60, as part of a broader research note on Solar names. The analyst states that the company is best-levered in his coverage to the tailwinds of the Inflation Reduction Act as the most immediate beneficiary of manufacturing credits as well as benefits from demand tailwinds given its above-80% exposure to the U.S. Lee also states that he has a more constructive outlook on First Solar's module gross margin recovery.
Yesterday oil was plunging and I mean plunging and which stocks were attracting the most buying? Semi's..? No.--> SOLAR STOCKS.
As an investor in the sector years past I can tell you it is the rare day oil goes down alot and Solar goes up. They always seem in a battle for the the same cash.
Yesterdays action told us that Green Energy ismore than a fad. It'smore than an offset to high oil it's about it'sown growth that isnot stopping.
Growth investors the same ones that might of bought tech, bought solar yesterday. Lots of it.
UPGRADE OF THE DAY-! -- This is a Double Upgrade from Sell to Buy <-- rare
Also it comes with a review of the whole sector and some stks like Shoals, SHLD downgraded. So this is a direct competition upgrade.... And lastly the price target boost is beyond significant $172 from $60.
First Solar upgraded to Buy from Sell at Goldman Sachs 20:53
FSLR
Goldman Sachs analyst Brian Lee upgraded First Solar to Buy from Sell with a price target of $172, up from $60, as part of a broader research note on Solar names. The analyst states that the company is best-levered in his coverage to the tailwinds of the Inflation Reduction Act as the most immediate beneficiary of manufacturing credits as well as benefits from demand tailwinds given its above-80% exposure to the U.S. Lee also states that he has a more constructive outlook on First Solar's module gross margin recovery.
First Solar (NASDAQ:FSLR) and Maxeon Solar Technologies (MAXN) on Wednesday were upgraded to Buy from a Sell rating at Goldman Sachs. The investment bank pointed to the tax-and-climate bill signed last month by President Biden as key drivers for the U.S. solar industry.
Conversely, Goldman Sachs downgraded Shoals Technologies Group (SHLS) to Sell from Buy and Canadian Solar (CSIQ) to Sell from Neutral because they’re less likely to benefit from the Inflation Reduction Act of 2022 (IRA).
The law has incentives for the biggest investment in energy-efficient products in U.S. history. It sets aside $21 billion for rebates and federal tax deductions for energy-saving improvements to people’s homes in the next 10 years.
“Simply put, we see stocks with U.S. leverage and/or U.S.-based manufacturing as fundamentally best positioned, and we take a deeper dive look at where valuation would suggest further upside exists,” Brian Lee, analyst at Goldman Sachs, said in the Sept. 7 note.
Conversely, Goldman Sachs downgraded Shoals Technologies Group (SHLS) to Sell from Buy and Canadian Solar (CSIQ) to Sell from Neutral because they’re less likely to benefit from the Inflation Reduction Act of 2022 (IRA).
The law has incentives for the biggest investment in energy-efficient products in U.S. history. It sets aside $21 billion for rebates and federal tax deductions for energy-saving improvements to people’s homes in the next 10 years.
“Simply put, we see stocks with U.S. leverage and/or U.S.-based manufacturing as fundamentally best positioned, and we take a deeper dive look at where valuation would suggest further upside exists,” Brian Lee, analyst at Goldman Sachs, said in the Sept. 7 note.
It's so funny to read this report and see that buying yesterday. Obviously GS told their sales force this yest... My guys were so tied up in this silly Apple crap we completely missed this.
Although I spotted the trend on Bloomberg. I didn't call it in.
Although I spotted the trend on Bloomberg. I didn't call it in.
Cathie Wood believes the Fed is 'making a mistake'
Sep. 08, 2022 7:13 AM
It's extremely painful but you end up learning so much.- Cathie Wood on the lead Alien's sexual maneuvers.
The innovation themed asset manager Cathie Wood believes that Jerome Powell and the Federal Reserve are miscalculating the outlook on inflation by increasing rates at such a steep pace.
Wood tweeted out: “Powell is using Volcker’s sledgehammer and, I believe, making a mistake.”
Wood continued with: “The Fed is basing monetary policy decisions on lagging indicators: employment and core inflation. Leading inflation indicators like gold and copper are flagging the risk of deflation. Even the oil price has dropped more than 35% from its peak, erasing most of the gain this year.”
For the upcoming September 21st Fed meeting futures are now pricing in an 82% chance that markets will see a 75-basis point hike compared to the 18% that are factoring a 50% rate hike.
It was just a month ago when markets were pricing in a 68% chance of a 75-basis point hike. Powell’s hawkish rhetoric delivered at the Jackson Hole economic symposium caused 14% swing, sending the target rate probability to 300-325 basis points for the upcoming Fed meeting.
Sep. 08, 2022 7:13 AM
It's extremely painful but you end up learning so much.- Cathie Wood on the lead Alien's sexual maneuvers.
The innovation themed asset manager Cathie Wood believes that Jerome Powell and the Federal Reserve are miscalculating the outlook on inflation by increasing rates at such a steep pace.
Wood tweeted out: “Powell is using Volcker’s sledgehammer and, I believe, making a mistake.”
Wood continued with: “The Fed is basing monetary policy decisions on lagging indicators: employment and core inflation. Leading inflation indicators like gold and copper are flagging the risk of deflation. Even the oil price has dropped more than 35% from its peak, erasing most of the gain this year.”
For the upcoming September 21st Fed meeting futures are now pricing in an 82% chance that markets will see a 75-basis point hike compared to the 18% that are factoring a 50% rate hike.
It was just a month ago when markets were pricing in a 68% chance of a 75-basis point hike. Powell’s hawkish rhetoric delivered at the Jackson Hole economic symposium caused 14% swing, sending the target rate probability to 300-325 basis points for the upcoming Fed meeting.
CHOO CHOO-! .... 1st plots are 2019 and the 2nd is 2021
